Research programme: muscle wasting disease therapies - Immusoft
Latest Information Update: 28 Sep 2024
At a glance
- Originator Immusoft
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Duchenne muscular dystrophy
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral, Injection)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral, Injection)
- 26 Aug 2020 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral) (Immusoft pipeline, August 2020)